ArticleJournal of Cancer2023
Analysis of Erythrocyte Sedimentation Rate Order in Epithelial Ovarian Cancer.
Article in Journal of Cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 3 citations in OpenAlex.
- Transporter Associated with Antigen Processing Proteins (TAP-1 and TAP-2) Gene Expression of MHC-I Downregulated in Oral Squamous Cell CarcinomaEndocrine, metabolic & immune disorders drug targets · 2026Article
- Investigation of ESR Values in the Diagnosis of Malignancies: A Cross-Sectional Study.Health science reports · 2025Article
- Red Cell Distribution Width as a Predictor of Survival in Patients with Hepatocellular Carcinoma.Medicina (Kaunas, Lithuania) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Erythrocyte sedimentation rate order (ESRO), platelet-lymphocyte ratio (PLR), red cell distribution width (RDW), and neutrophil-lymphocyte ratio (NLR) are hematological parameters that reflect the presence of biomarkers in epithelial ovarian cancer (EOC). This study evaluated the best haematological parameter in order to distinguish between EOC patients and healthy individuals. There were a total of 33 patients with EOC as subjects treated in Dr. Sardjito hospital, Yogyakarta, Indonesia and 32 volunteer subjects as controls. Curves of receiver operation, area under the curve, specificity, and sensitivity were estimated. To demonstrate EOC's presence, the ESRO was better than the hematological parameters of RDW, PLR, and NLR (AUC = 0.9245, 0.9010, 0.8351, and 0.7457, respectively; sensitivity and specificity = 83.3 and 90.6; 88.9 and 87.5; 100.0 and 68.8; and 94.4 and 53.1, respectively) at the cut-off points 1,125, 44.2, 163.2, and 2,551. Hence, ESRO is a better parameter to indicate the presence of EOC compared to RDW, PLR and NLR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.